Caixa Capital Risc leads €2.4m round for GlyCardial

Local healthcare seed investor HealthEquity also took part in the transaction.

The company aims to use the fresh capital to finalise the clinical phase of its product within the next three years. Furthermore, at completion of the clinical phase, the business hopes to develop a device that allows the treatment to be administered in ambulances.

Caixa Capital Risc is the venture capital branch of Spanish asset manager Criteria Caixa. Currently the GP has €200m in assets under management and manages eight investment vehicles with 195 portfolio companies. These mainly operate in the technologies and life sciences sectors.

Company
GlyCardial span out from the Barcelona-based institute of biotechnologies Instituto Catalán de Ciencias Cardiovasculares (ICCC) in September 2017. The business develops a blood test treatment based on a protein called Apo J-Glyc and focuses on cardiovascular dysfunctions.

People
GlyCardial Diagnostics – Judit Cubedo (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• Healthcare
• Southern Europe
• Venture
• Spain
• Caixa Capital Risc